AzTrials
AzTrials

Spinal StenosisNCT01892878

Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device

A study testing VerteLoc in people with Spinal Stenosis, run by VG Innovations, LLC at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The purpose of this clinical study is to evaluate fusion of the facet joints in a prospective cohort of patients utilizing the VerteLoc facet fixation device in patients receiving lumbar laminectomy (L1-S1), without ancillary stabilization devices such as pedicle and transfacet screws. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Spinal Stenosis
What is being tested?
VerteLoc
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
Jul 2013to 1 Jan 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Have provided consent for research by signing the Institutional Review Board approved Informed Consent;
  • Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care;
  • Are skeletally mature, and are at least 18 years of age;
  • If female, are not pregnant;
  • Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.

Who cannot join

  • Previous surgery at the target or adjacent vertebral levels;
  • More than two intervertebral levels to be treated by the laminectomy procedure;
  • Found to be inappropriate candidates for facet fixation using the VerteLoc system;
  • Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables;
  • Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses,
  • Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery;
Show all 11Show fewer
  • Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
  • BMI >40% ;
  • History of tobacco smoking within the past 6 months;
  • Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
  • Are participating in any other clinical trial.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Genesys Regional Medical Center

    Grand Blanc, Michigan, 48439

Other trials in United States

About this study

Official title: A Prospective, Single Arm Clinical Trial Evaluating Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device

The purpose of this clinical study is to evaluate fusion of the facet joints in a prospective cohort of patients utilizing the VerteLoc facet fixation device in patients receiving lumbar laminectomy (L1-S1), without ancillary stabilization devices such as pedicle and transfacet screws.

Read the detailed description

Study Design: Non-randomized, prospective, single arm clinical trial

Patient Population and Sample Size: Patients (n=25) from up to 2 clinical site, who have been medically evaluated, found appropriate for, and have agreed to treatment by lumbar decompressive laminectomy and facet fixation, including unilateral and/or bilateral posterolateral fusion according to accepted medical standards.

Objectives:

The primary objective of this study is to:

  1. Evaluate the fusion status of facet joints following laminectomy and facet fixation using the VerteLoc system in combination with unilateral and/or bilateral posterolateral fusion.
  2. Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at 2-3 weeks, 3 months, and 12 months.

The secondary objectives of this study are to:

  1. Explore the effect of preoperative bone density on facet fusion status;
  2. Assess the ease of use of the VerteLoc system;
  3. Record operative time using the VerteLoc system;
  4. Monitor the occurrence of adverse events related or possibly related to the use of the VerteLoc system;
  5. Monitor the occurrence of subsequent surgical intervention at the target level(s).
  6. Subject success/Clinical outcome (Assess additional improvement criteria)
  7. Evaluate Fusion rate in relations to DEXA value

Inclusion Criteria: Candidates must meet ALL of the following:

  1. Have provided consent for research by signing the Institutional Review Board approved Informed Consent;
  2. Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care;
  3. Are skeletally mature, and are at least 18 years of age;
  4. If female, are not pregnant;
  5. Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.

Exclusion Criteria:

  1. Previous surgery at the target or adjacent vertebral levels;
  2. More than two intervertebral levels to be treated by the laminectomy procedure;
  3. Found to be inappropriate candidates for facet fixation using the VerteLoc system;
  4. Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables;
  5. Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses,
  6. Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery;
  7. Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
  8. BMI >40% ;
  9. History of tobacco smoking within the past 6 months;
  10. Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
  11. Are participating in any other clinical trial. Study Duration : 12 months

Study Outcomes:

The primary study outcomes of this study are:

  1. Fusion grade at 12 month follow-up using CT scans with a grading system based on:
  2. Complete fusion;
  3. Partial fusion;
  4. No fusion;
  5. Subject success / Clinical outcome:

Evaluate the reduction in baseline VAS back pain score at:

  1. 2-3 weeks
  2. 3 months
  3. 12 months.

The secondary outcomes of this study are:

  1. Statistical correlation of DEXA scan bone mass density score to CT and radiographic fusion status;
  2. Surgeon opinion of "ease of use" utilizing the VerteLoc system (0-10);
  3. Operative time (minutes) from surgical access to completion of device placement
  4. Occurrence and prevalence of adverse events related or possibly related to the use of the VerteLoc System;
  5. Occurrence of subsequent surgical intervention at the target level(s).

Study Assessments

  • Intraoperative: Post-placement radiograph;
  • 12 months: A/P and lateral flexion and extension lumbar radiograph and lumbar CT scan.

Statistical Analysis

  • Student t-tests
Conditions
Spinal Stenosis
Being tested
VerteLoc
Medical subject headings
Spinal Stenosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VerteLocProcedure or surgery

    Single Arm

Study groups in NCT01892878
Study groupRoleWhat they receive
Single Arm StudyOtherAll patients will receive treatment
Receives: Procedure: VerteLoc

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fusion grade at 12 month follow-up using CT scans

    Fusion grade at 12 month follow-up using CT scans with a grading system based on:

    1. Complete fusion;
    2. Partial fusion;
    3. No fusion;

    Measured: 12 months

Secondary outcomes (1)
  1. Subject success / Clinical outcome

    Subject success / Clinical outcome:

    Evaluate the reduction in baseline VAS back pain score.

    Measured: 2-3 weeks, 3 months and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jul 2013 (estimated)
  2. Study startJul 2013
  3. Primary completionJul 2015 (estimated)
  4. Study completion1 Jan 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01892878
Sponsor's protocol ID
VGI-002
Status last verified
Jul 2013
First submitted
1 Jul 2013
Last updated
16 Mar 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing VerteLoc in people with Spinal Stenosis, run by VG Innovations, LLC at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 16 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fusion grade at 12 month follow-up using CT scans (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in